Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00199216PMID 2787695PMCID PMC11038020
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor

  2004cited by this paper
• Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

  2004cited by this paper
• Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Effect of melphalan in vitro on induction of murine suppressor T cells by ConA

  2004cited by this paper
• Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan.

  1988cited by this paper
• Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.

  1988cited by this paper
• Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.

  1987cited by this paper
• Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.

  1985cited by this paper
• Effect of melphalan administration on the activity of natural killer and natural cytotoxic spleen cells of normal and tumor-bearing mice.

  1985cited by this paper
• Effects of the methanol extract residue (MER) tubercle bacillus fraction on the production of antibodies in vitro. II. Effects on macrophage and lymphocyte populations.

  1984cited by this paper
• Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.

  1979cited by this paper
• Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.

  1979cited by this paper
• Myeloma-induced immunosuppression: a multistep mechanism.

  1978cited by this paper
• A miniaturized in vitro diffusion culture system.

  1978cited by this paper
• Lymphocyte Defect in Plasmacytoma-bearing Mice

  1978cited by this paper
• The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315-tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells

  1978influential reference
• The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.

  1975cited by this paper
• A simple method for the removal of antibody-forming cells from whole spleen cell populations.

  1974cited by this paper
• INFLUENCE OF DOSE AND ROUTE OF ANTIGEN INJECTION ON THE IMMUNOLOGICAL INDUCTION OF T CELLS

  1974cited by this paper
• A rapid method for the isolation of functional thymus‐derived murine lymphocytes

  1973cited by this paper
• Effect of Plasma Cell Tumor on Antibody Production by Mouse Spleen Cells

  1968cited by this paper
• Further improvements in the plaque technique for detecting single antibody-forming cells.

  1968cited by this paper
• Effect of transplantable plasma-cell tumors on antibody response in mice.

  1962cited by this paper

• Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.

  2001cites this paper
• Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2.

  1999cites this paper
• One Hundred Years of Cancer Immunotherapy: A Critical Appraisal

  1997cites this paper
• Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative

  1995cites this paper
• Inhibitors of lymphocyte activation secreted by human melanoma cell lines

  1990cites this paper